Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.

about

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.

Item

http://www.wikidata.org/entity/Q55057566

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@en

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@nl

type

Item

label

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@en

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@nl

prefLabel

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@en

Pegfilgrastim for primary prop ...... s undergoing TAC chemotherapy.

@nl

P1476

Pegfilgrastim for primary prop ...... ts undergoing TAC chemotherapy

@en

P2093

Jihyoun Lee

http://www.w3.org/2001/XMLSchema#string

Jong Eun Lee

http://www.w3.org/2001/XMLSchema#string

Min Hyuk Lee

http://www.w3.org/2001/XMLSchema#string

Sun Wook Han

http://www.w3.org/2001/XMLSchema#string

Sung Mo Hur

http://www.w3.org/2001/XMLSchema#string

Sung Yong Kim

http://www.w3.org/2001/XMLSchema#string

Zisun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.

Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

P304

223-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4174/ASTR.2018.94.5.223

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cheol Wan Lim

P577

2018-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29732352

http://www.w3.org/2001/XMLSchema#string

P932

5931931

http://www.w3.org/2001/XMLSchema#string